Poly(ethylene glycol) based nanotubes for tuneable drug delivery to glioblastoma multiforme.
Journal
Nanoscale advances
ISSN: 2516-0230
Titre abrégé: Nanoscale Adv
Pays: England
ID NLM: 101738708
Informations de publication
Date de publication:
13 Oct 2020
13 Oct 2020
Historique:
received:
10
06
2020
accepted:
20
08
2020
entrez:
22
9
2022
pubmed:
24
8
2020
medline:
24
8
2020
Statut:
epublish
Résumé
Glioblastoma multiforme (GBM) is the most aggressive type of malignant brain tumour, which is associated with a poor two-year survival rate and a high rate of fatal recurrence near the original tumour. Focal/local drug delivery devices hold promise for improving therapeutic outcomes for GBM by increasing drug concentrations locally at the tumour site, or by facilitating the use of potent anti-cancer drugs that are poorly permeable across the blood brain barrier (BBB). For inoperable tumours, stereotactic delivery to the tumour necessitates the development of nanoscale/microscale injectable drug delivery devices. Herein we assess the ability of a novel class of polymer nanotube (based on poly(ethylene glycol) (PEG)) to load doxorubicin (a mainstay breast cancer therapeutic with poor BBB permeability) and release it slowly. The drug loading properties of the PEG nanotubes could be tuned by varying the degree of carboxylic acid functionalisation and hence the capacity of the nanotubes to electrostatically bind and load doxorubicin. 70% of the drug was released over the first seven days followed by sustained drug release for the remaining two weeks tested. Unloaded PEG nanotubes showed no toxicity to any of the cell types analysed, whereas doxorubicin loaded nanotubes decreased GBM cell viability (C6, U-87 and U-251) in a dose dependent manner in 2D
Identifiants
pubmed: 36132909
doi: 10.1039/d0na00471e
pii: d0na00471e
pmc: PMC9418774
doi:
Types de publication
Journal Article
Langues
eng
Pagination
4498-4509Informations de copyright
This journal is © The Royal Society of Chemistry.
Déclaration de conflit d'intérêts
There are no conflicts to declare.
Références
Nanomedicine (Lond). 2006 Jun;1(1):39-50
pubmed: 17716208
J Neurooncol. 2016 Jan;126(2):235-42
pubmed: 26530267
Science. 2002 Jun 14;296(5575):1997
pubmed: 12065828
Expert Rev Anticancer Ther. 2013 Dec;13(12):1453-61
pubmed: 24236823
Curr Oncol. 2007 Oct;14(5):189-94
pubmed: 17938702
Cell Rep. 2014 Oct 9;9(1):349-365
pubmed: 25263561
MethodsX. 2020 Jan 23;7:100805
pubmed: 32071891
J Am Chem Soc. 2005 Jun 22;127(24):8586-7
pubmed: 15954751
Proc Natl Acad Sci U S A. 2011 Jul 5;108(27):10952-7
pubmed: 21690348
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Brain. 2019 Mar 1;142(3):512-525
pubmed: 30808022
Chem Commun (Camb). 2017 Nov 28;53(95):12826-12829
pubmed: 29143021
Clin Pharmacokinet. 2003;42(5):419-36
pubmed: 12739982
Neuron. 2018 Aug 22;99(4):702-719.e6
pubmed: 30078576
J Pharm Sci. 2010 Jul;99(7):3122-31
pubmed: 20166203
Chem Rev. 2020 Feb 26;120(4):2347-2407
pubmed: 32013405
J Breast Cancer. 2013 Jun;16(2):164-70
pubmed: 23843848
Biomaterials. 2020 Feb;230:119540
pubmed: 31759681
Nanomedicine (Lond). 2012 Oct;7(10):1485-94
pubmed: 22712575
J Clin Neurosci. 2015 Dec;22(12):1889-94
pubmed: 26279503
PLoS One. 2015 Jul 17;10(7):e0132266
pubmed: 26186224
J Pharm Pharmacol. 2002 Feb;54(2):159-80
pubmed: 11848280
J Clin Neurosci. 2011 Nov;18(11):1444-8
pubmed: 21813279
J Interdiscip Nanomed. 2016 Apr;1(1):9-18
pubmed: 27512602
Int J Radiat Oncol Biol Phys. 1989 Jun;16(6):1405-9
pubmed: 2542195
Neurochem Res. 2009 May;34(5):984-90
pubmed: 18937067
Neuro Oncol. 2015 Mar;17 Suppl 2:ii9-ii23
pubmed: 25746091
Int J Pharm. 2019 Mar 25;559:220-227
pubmed: 30703501
ACS Nano. 2015 Aug 25;9(8):7815-30
pubmed: 26043308
Int J Nanomedicine. 2012;7:2661-71
pubmed: 22679376
Nanoscale. 2012 Mar 21;4(6):1910-8
pubmed: 22159164
SLAS Technol. 2017 Aug;22(4):454-465
pubmed: 27272155
Chem Commun (Camb). 2008 Jan 28;(4):459-61
pubmed: 18188467
Contemp Clin Trials. 2012 Mar;33(2):320-31
pubmed: 22101221
Neuro Oncol. 2003 Apr;5(2):79-88
pubmed: 12672279
J Control Release. 2016 Nov 10;241:200-219
pubmed: 27693751
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2018 Jan;10(1):
pubmed: 28544801
JAMA. 2013 Nov 6;310(17):1842-50
pubmed: 24193082
J Control Release. 2016 Dec 10;243:29-42
pubmed: 27693428
J Control Release. 2016 Mar 10;225:301-13
pubmed: 26826308
Oncol Res. 2004;14(7-8):325-30
pubmed: 15301423
Pharm Res. 2000 Jul;17(7):776-81
pubmed: 10990194
Sci Rep. 2015 Dec 01;5:17478
pubmed: 26619814
Br J Cancer. 1996 Jul;74(2):187-93
pubmed: 8688320
Neuro Oncol. 2012 Mar;14(3):351-9
pubmed: 22241797
Nanoscale. 2018 May 10;10(18):8413-8421
pubmed: 29714385
Oncology. 2010;78(2):103-14
pubmed: 20357518
Strahlenther Onkol. 2000 Sep;176(9):422-8
pubmed: 11050916
Biomaterials. 2015;53:609-20
pubmed: 25890757
Carbohydr Polym. 2020 Oct 1;245:116504
pubmed: 32718615
J Control Release. 2017 Oct 28;264:45-54
pubmed: 28830791
Mol Neurobiol. 2018 May;55(5):4185-4194
pubmed: 28612256
Cell Mol Life Sci. 2017 Jul;74(13):2451-2466
pubmed: 28210785
Int J Pharm. 2001 Feb 1;213(1-2):103-16
pubmed: 11165098
Exp Neurol. 2013 Sep;247:485-95
pubmed: 23360805
Science. 1994 Dec 23;266(5193):1961-6
pubmed: 17836514
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Biomaterials. 2007 Jul;28(20):3083-90
pubmed: 17428534
J Neurosurg. 1991 Oct;75(4):559-63
pubmed: 1653309
ACS Biomater Sci Eng. 2017 May 8;3(5):787-792
pubmed: 33440492